ProteinLogic appoints Dr Alex Betz as Chief Scientific Officer

CAMBRIDGE, UK (2016-05-03) – ProteinLogic, the biomarker discovery and exploitation company, has appointed Dr Alex Betz as Chief Scientific Officer to manage the scientific, research, technological and developmental operations. As a long standing non-executive director of the Company, Alex has helped set the company research and scientific priorities so that they line up with the overall mission and goals of the Company

Dr Betz completed a PhD on the hypermutation of immunoglobulin genes at the MRC Laboratory of Molecular Biology, Cambridge UK. After 3.5 years working as a post-doc at the Howard Hughes Medical Institute, Johns Hopkins University, Baltimore USA, he was recruited back to the MRC Laboratory of Molecular Biology. His initial research interest was the regulation of lymphocyte migration by chemokines. In 2004 he published his group’s breakthrough discovery that regulatory T cells maintain maternal tolerance to the fetus.  He retired from academic research in 2015 and now focuses on helping commercial projects.

Alex commented  “I am pleased to take on this role in ProteinLogic. I have been involved with the company from an early stage and am delighted to take on this role in developing its biomarker signature for Tuberculosis as well as a pipeline of other diseases. I am excited by the huge potential that ProteinLogic holds and look forward to shaping these opportunities and bringing tests to the market that can make a real impact to people’s health”.

ProteinLogic’s Chairman Mahesh Shah said: “We are delighted to welcome Alex to this new role at ProteinLogic. Whilst we have had the benefit of Alex’s scientific rigour as a NED, his appointment as Chief Scientific Officer will be a catalyst to the development of diagnostic tests and biomarker discovery programs. We look forward to working with him as he plays a significant role in the further development of the Company’s vision of developing a discovery platform for biomarkers and a point-of-care platform for the early diagnosis of Tuberculosis.”

Further information:

Mahesh Shah, ProteinLogic Ltd,


ProteinLogic is a biomarker discovery and exploitation company developing novel diagnostic products that address key unmet medical needs in infection and inflammatory diseases. The first product in the pipeline is a novel diagnostic blood test for tuberculosis. The Company has developed a proprietary biomarker technology (ImmiPrint®) with potential to diagnose early onset of diseases, and to provide information as to how a disease is likely to develop and respond to particular drug treatments. The technology is based upon the profiling of a discrete subset of immune system proteins found in blood and other body fluids.